Number of eligible people: CDEC talked over the uncertainty in the volume of people with reasonably significant to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some people who will be labeled as obtaining moderate or moderate illness may have a https://hemgenix28261.designi1.com/56752996/not-known-factual-statements-about-hemgenix